Comparison · NCT02881008-d293a675
Arm D vs Arm F: Proportion of Patients With HBV DNA Response at Week 24 of Therapy
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm D vs Arm F: Proportion of Patients With HBV DNA Response at Week 24 of Therapy. Trial comparisons, record NCT02881008-d293a675. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02881008-d293a675
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.875 | 0.529 | 0.978 | wilson | |
| Risk in group 2 | 0.75 | 0.409 | 0.929 | wilson | |
| Risk difference, group 1 minus group 2 | 0.125 | -0.264 | 0.481 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.17 | 0.723 | 1.88 | log | |
| Odds ratio, group 1 over group 2 | 2.33 | 0.167 | 32.6 | log | |
| Number needed to treat, for one more participant with the outcome on Arm D than on Arm F | 8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm D | Entecavir 0.5 mg daily for 24 weeks | 7 | 8 | OG000 |
| Group 2 | Arm F | Myrcludex B 10 mg daily for 24 weeks, followed by 12 weeks follow-up period | 6 | 8 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Proportion of Patients With HBV DNA Response at Week 24 of Therapy
- Description
- HBV DNA response is defined as persistent reduction of HBV DNA by \>1 log IU/ml or negativation at week 24 compared to baseline.
- Time frame
- 24 weeks
- Population
- This variable was assessed in the patients administered 24-week treatment: patients of Arm F who received Myrcludex B 10 mg and patients of Arm D who received Entecavir 0.5 mg.
Source ClinicalTrials.gov
Trial
- Title
- Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B
- NCT number
- NCT02881008
- Phases
- PHASE1, PHASE2
- Conditions
- Chronic Hepatitis B
- Interventions
- Entecavir, Myrcludex B
- Lead sponsor
- Hepatera Ltd.
- Results first posted
- 2018-09-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02881008?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02881008-d293a675